New Research In
Physical Sciences
Social Sciences
Featured Portals
Articles by Topic
Biological Sciences
Featured Portals
Articles by Topic
- Agricultural Sciences
- Anthropology
- Applied Biological Sciences
- Biochemistry
- Biophysics and Computational Biology
- Cell Biology
- Developmental Biology
- Ecology
- Environmental Sciences
- Evolution
- Genetics
- Immunology and Inflammation
- Medical Sciences
- Microbiology
- Neuroscience
- Pharmacology
- Physiology
- Plant Biology
- Population Biology
- Psychological and Cognitive Sciences
- Sustainability Science
- Systems Biology
Therapeutic B cell depletion impairs adaptive and autoreactive CD4+ T cell activation in mice
-
Edited by Max D. Cooper, University of Alabama, Birmingham, AL, and approved November 5, 2007 (received for review September 28, 2007)

Abstract
CD20 antibody depletion of B lymphocytes effectively ameliorates multiple T cell-mediated autoimmune diseases through mechanisms that remain unclear. To address this, a mouse CD20 antibody that depletes >95% of mature B cells in mice with otherwise intact immune systems was used to assess the role of B cells in CD4+ and CD8+ T cell activation and expansion in vivo. B cell depletion had no direct effect on T cell subsets or the activation status of CD4+ and CD8+ T cells in naive mice. However, B cell depletion impaired CD4+ T cell activation and clonal expansion in response to protein antigens and pathogen challenge, whereas CD8+ T cell activation was not affected. In vivo dendritic cell ablation, along with CD20 immunotherapy, revealed that optimal antigen-specific CD4+ T cell priming required both B cells and dendritic cells. Most importantly, B cell depletion inhibited antigen-specific CD4+ T cell expansion in both collagen-induced arthritis and autoimmune diabetes mouse models. These results provide direct evidence that B cells contribute to T cell activation and expansion in vivo and offer insights into the mechanism of action for B cell depletion therapy in the treatment of autoimmunity.
Footnotes
- ‡To whom correspondence should be addressed: Department of Immunology, Box 3010, Duke University Medical Center, Durham, NC 27710. E-mail: thomas.tedder{at}duke.edu
-
Author contributions: J.-D.B. and K.Y. contributed equally to this work; J.-D.B., K.Y., J.C.P., and T.F.T. designed research; J.-D.B., K.Y., and G.M.V. performed research; J.-D.B., K.Y., and Y.W. contributed new reagents/analytic tools; J.-D.B., K.Y., R.M.T., J.C.P., and T.F.T. analyzed data; and J.-D.B., K.Y., G.M.V., R.M.T., J.C.P., and T.F.T. wrote the paper.
-
Conflict of interest statement: T.F.T. is a paid consultant for MedImmune, Inc. and a consultant and shareholder for Angelica Therapeutics, Inc. J.C.P is a paid consultant for Angelica Therapeutics, Inc.
-
This article is a PNAS Direct Submission.
-
This article contains supporting information online at www.pnas.org/cgi/content/full/0709205105/DC1.
- © 2007 by The National Academy of Sciences of the USA